



Tufts Center for the Study of Drug Development

TUFTS UNIVERSITY

Impact REPORT

ANALYSIS AND INSIGHT INTO CRITICAL DRUG DEVELOPMENT ISSUES

75% of U.S. health plans reimburse off-label uses of prescription drugs

Reimbursement based mainly on published pharmaceutical compendia

- Off-label use has proliferated over the last decade, especially with monoclonal antibodies and other biologicals.
- About one-quarter of U.S. health plans do not reimburse for off-label use.
- Of the plans that reimburse off-label uses, over half impose conditions, including step therapy, indication restrictions, prior authorization, and quantity limits.
- Nearly 90% of survey respondents say pharmaceutical compendia form a basis for off-label use reimbursement decisions.
- Three-quarters of plans ascribe a very important role to peer-reviewed literature in off-label use reimbursement decisions.